The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
about
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsSafe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingImatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaTargeted therapy for advanced renal cell carcinomaTargeted therapy for advanced renal cell carcinomaBcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylationStructural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.Charting the molecular network of the drug target Bcr-AblMolecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitorsCombinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90Farnesyl transferase inhibitor resistance probed by target mutagenesisAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainAberrant Wnt Signaling in LeukemiaReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsChronic myeloid leukemia: reminiscences and dreamsInflammatory bowel disease as a model for translating the microbiomeCell-to-cell variability in cell death: can systems biology help us make sense of it all?Strength and specificity of the CMBA screening platform for bioactive molecules discoveryThe tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injuryMicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia CellsSmall Molecule Recognition of c-Src via the Imatinib-Binding ConformationThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits LeukemogenesisAxitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationThe 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognitionPonatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE studyTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentMultiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functionsPotential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsTowards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsTyrosine kinase inhibitors for the treatment of rheumatoid arthritisAHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.
P2860
Q21195221-28BC2297-0789-4192-B33F-F57493E0F119Q23923997-8DAC7784-70D2-46E9-9592-C3C91CBF245FQ24186877-389277F9-8965-40DE-9A4F-9A980FAA6292Q24241730-91D28F04-B3CD-48DC-814F-4B48717CC97CQ24242946-03B9AA42-3962-45E3-9284-B573383ADDE5Q24244090-D5C9ED37-5841-485C-A069-4D0A5109E2CAQ24298234-61DDC305-5FDD-4EE9-8701-6F6440051260Q24307789-ED7FD47B-CF2D-453B-A2C0-B19F90A4DC00Q24317707-9557C230-D3F6-4F98-BAD6-907D4461F415Q24336197-ADDAB6EE-4940-405C-A212-A457397B4A68Q24647585-9E9A6A72-FB0D-4BFC-8B44-21025497CA13Q24684154-F34C9011-8781-4123-9D68-4BBF2FDC7415Q24794765-03FD8C3D-9D7C-4968-A70A-453E1E87913FQ26738411-1B98AABC-C99B-485D-894B-695DA422E219Q26740953-1DAEF9A1-58B0-4822-B916-56B5C53332B8Q26748769-6ED344A5-4071-4975-8174-22843834B42AQ26853123-EA74EA29-1789-4E4D-BB32-1CE6279281F7Q27013063-3CD9CB0D-56D1-4A44-9464-288B170CDD34Q27014820-E9A1AC10-BAEA-479E-95F7-AC6A8A0FA68EQ27305276-D216ADFB-5C14-46ED-98ED-912CDA5271B8Q27343176-5D018762-D9F6-4FE5-B66F-DDB37FEEB846Q27652602-034A1662-EE1F-411A-A4C5-2C4691C9DBCBQ27653890-3948D983-E623-4BCD-AC9D-6F32751F667AQ27675049-EAF1E450-CB7A-4A00-ADA0-4A600A7AEFCDQ27698001-61FA843D-4CD6-4FAC-BE0D-1BCF4B92BA65Q27698320-9FBFAC82-9593-4851-B587-CCFC0CF319ACQ27852657-0C335E6F-60F2-4026-B2B1-2C5B29A55312Q28076462-3BB9EA2E-B21C-4E89-ADBC-4D1B98D0C57BQ28115996-834AF205-5640-4C22-BC1B-48A82C8E32BCQ28391383-9D1E0FED-8C6F-4BC4-9332-BCEF1353D112Q28469345-D9BCB3BD-A90D-4546-91AF-A8E84ECC0E5AQ28477903-CA4CC206-FCDD-49D1-A5D8-29E5424E99DAQ28540547-DFF539D5-CA26-4000-A64D-1A971843CA17Q28545195-4E2105B4-004A-47BE-B1D7-EB1B3D0E3B5DQ28551159-AFD10219-9A3B-49A6-A1AB-3651F21B30A3Q28586026-B4670500-9797-43D8-A182-487185C14507Q28674280-0E70CC13-A145-4948-9A9A-0A1B918F88E6Q30010179-CCF70B0F-0FB8-4720-9945-0BBC49B869F1Q30155948-12A75E73-D0B9-43E0-9F71-3B8CCBD1A979Q30160084-D3DE88C6-E66D-41DB-B24F-B6EA0FCEC8B3
P2860
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@ast
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@en
type
label
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@ast
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@en
prefLabel
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@ast
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@en
P1433
P1476
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
@en
P2093
Elisabeth Buchdunger
Michael Deininger
P304
P356
10.1182/BLOOD-2004-08-3097
P407
P577
2004-12-23T00:00:00Z